Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Magnetic Resonance Imaging of Aortic Aneurysm Instability

The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2010 by University of Edinburgh.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
British Heart Foundation
Information provided by:
University of Edinburgh
ClinicalTrials.gov Identifier:
NCT00794092
First received: November 17, 2008
Last updated: April 7, 2010
Last verified: April 2010

November 17, 2008
April 7, 2010
November 2008
August 2010   (final data collection date for primary outcome measure)
Change in signal intensity in a Region of Interest on MRI scanning [ Time Frame: 24 hours after administration of Sinerem ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00794092 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Magnetic Resonance Imaging of Aortic Aneurysm Instability
Magnetic Resonance Imaging of Aortic Aneurysm Instability

Abdominal aortic aneurysm (AAA) is a progressive enlargement of the aorta, the largest blood vessel in the body. It is at risk of bursting when it is usually fatal. Currently the risk of the AAA bursting is estimated from its diameter. In this study, the investigators hope to develop a new type of aneurysm scan involving Magnetic Resonance Imaging (MRI). It is hoped that this scan will be better at determining which AAAs are at risk of bursting and therefore require an operation to prevent this.

Abdominal aortic aneurysms (AAA) have a prevalence of ~5% and when ruptured carry a mortality rate of ~90%. The pathophysiology of AAA encompasses a range of poorly understood biomechanical and biological processes. Currently the diameter of the aneurysm is used as a surrogate for the risk of rupture and patients with an aneurysm diameter greater than 55 mm are considered for elective surgical repair. However, this reliance on a single surrogate measure is too simplistic and does not take into account other physical and biological aspects of the AAA. We propose to evaluate the role of inflammation, proteolysis and neovascularisation in patients with AAA disease. We will compare novel magnetic resonance imaging techniques with blood and tissue measures of inflammation (c-reactive protein, cytokines, macrophage and leucocyte density), proteolytic activity (matrix metalloproteinases, tissue inhibitors of metalloproteinases) and neovascularisation (vessel density, endothelial progenitor cells). By comparing findings between patients with symptomatic and asymptomatic disease, this study will inform our understanding of the disease process as well as potentially identify risk markers of AAA instability that could be used to follow-up patients with asymptomatic disease.

Interventional
Phase 2
Phase 3
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Aortic Aneurysm
Drug: Sinerem administration
Single dose
Experimental: Sinerem
MRI scanning of patients with AAA before and 24hrs +/- 4hrs after administration of Sinerem
Intervention: Drug: Sinerem administration
Richards JM, Semple SI, MacGillivray TJ, Gray C, Langrish JP, Williams M, Dweck M, Wallace W, McKillop G, Chalmers RT, Garden OJ, Newby DE. Abdominal aortic aneurysm growth predicted by uptake of ultrasmall superparamagnetic particles of iron oxide: a pilot study. Circ Cardiovasc Imaging. 2011 May;4(3):274-81. doi: 10.1161/CIRCIMAGING.110.959866. Epub 2011 Feb 8.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
60
August 2010
August 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • AAA measuring >40mm in AP diameter on ultrasound scanning
  • Age >40 years (patients younger than this with AAA may have a connective tissue disorder and a different aetiology to their disease)
  • Considered to be suitable for standard infra−renal open surgical repair

Exclusion Criteria:

  • Patients who are not deemed to be fit for open surgical repair
  • Patients who are deemed to be suitable for a stent graft performed by the radiologists rather than the standard operation
  • Contraindication to MRI scanning identified from MRI Safety Questionnaire (see attached)or claustrophobia
  • Age <40 years
  • Patients requiring emergent repair such that there is insufficient time available to complete the protocol
  • Patients refusing to give consent
  • Patients unable to give consent
  • Pregnant women (contrast is teratogenic in animals)
  • Intercurrent illness (may confound the results)
  • Patients with a systemic inflammatory disorder or underlying malignancy
  • Patients who require an emergency operation such that there is insufficient time to complete the study protocol
  • Renal dysfunction (Creat >250 or eGFR<25)
  • Hepatic dysfunction (Child's grade B or C)
Both
40 Years and older
No
Contact: Jennifer MJ Richards 01312423621 jenny.richards@ed.ac.uk
Contact: David E Newby 01312426515 d.e.newby@ed.ac.uk
United Kingdom
 
NCT00794092
2007/R/CAR/15
No
Elspeth Currie, University of Edinburgh
University of Edinburgh
British Heart Foundation
Principal Investigator: David E Newby University of Edinburgh
University of Edinburgh
April 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP